Van:	5.1.2.e Woo		
Aan:	5.1.2.e Woo @ec.europa.eu"; <sup>5.1.2 e Woo</sup> @nebih.gov.hu; <sup>51.2 e Woo</sup>		
	@nebih.gov.hu		
Cc:	5.1.2.e Woo <u>@efsa.europa.eu;</u> 5.1.2.e Woo <u>@ec.europa.eu;</u>		
	5.1.2.e Woo @ec.europa.eu; 5.1.2.e Woo @ec.europa.eu; 5.1.2.e Woo @ec.europa.eu;		
	5.1.2.e Woo defsa.europa.eu; 5.1.2.e Woo dec.europa.eu; 5.1.2.e Woo defsa.europa.eu;		
	5.1.2.e Woo		
Onderwerp:	Re: AGG communication		
Datum:	woensdag 27 maart 2019 18:51:11		

 $\mathbf{Dear}^{5.12 \text{ e Woo}}$ , 5.12 e Woo and all,

<sup>2.e Woo</sup>: Thank you for sharing the positive news on the transparency initiative from Bayer.

and <sup>112ewo</sup>: The communication agency you are proposing seems like an interesting option indeed. You have a green light from us to go ahead and contact them to investigate this opportunity further.

Regarding a possible press briefing I would like to ask for a clarification, to able to comment on the proposal: Who do you think should lead the press meeting, and at what point in time do you think it should be arranged?

Kind regards,

Communications Secretariat Swedish Chemicals Agency Direct: +46 5.1.2.e Woo Tel: +46 5.1.2.e Woo www.kemikalieinspektionen.se How we treat your personal data

Från:	5.1.2.e Woo @anses.fr	>	
Skick	at: den 27 mars 2019 18:26		
Till:	5.1.2.e Woo	@ctgb.nl>; 5.1.2.e Woo@	ec.europa.eu'
5.1.2.	e Woo@ec.europa.eu>; 5.1.2.e Woo@n	ebih.gov.hu; 5.1.2.e Woo	-
	@kemi.se>;	5.1.2.e Woo	@ctgb.nl>;
5.1.2.e Woo	@nebih.gov.hu		0
Kopia	: 5.1.2.e Woo @efsa.europ	oa.eu; 5.1.2.e Woo @ec	
5.1	.2.e Woo @ec.europa.eu; 5.1.2	2.e Woo @ec.europa.eu;	
5.1.	2.e Woo @ec.europa.eu; 5.1.2.e	Woo @efsa.europa.eu;	
5.1.	2.e Woo @ec.europa.eu; 5.1.2.	e Woo @efsa.europa.eu;	5.1.2.e Woo
	@kemi.se>; 5.1.2		
	DT: ACC		

Amne: RE: AGG communication

Dear Dear colleagues,

Thanks for your suggestions. I will come back later with the French feedback.

I would like to inform you about the initiave Bayer has just shared with us on transparency on the data generated for the last renewal of glyphosate. This goes in the right direction.

Kind regards,

5.1.2.e Woo

De :	5.1.2.e Woo	[AG/5040] <5.1.2.e Woo@bayer.com>	
Envoy	é : mercredi 27 mars 2	019 13:13	
À:	5.1.2.e Wo	anses.fr>	
Cc:		5.1.2.e Woo	<u>@bayer.com</u> >;
5.1.	2.e Woo <i>@anses</i>	. <u>.fr</u> >	

Objet : Public accessibility of Bayer-owned glyphosate safety studies

## Dear<sup>5.1.2.e Woo</sup>,

As you are well aware, the safety of glyphosate and other crop protection tools continues to be a topic that drives public conversation. Bayer understands people want more information regarding the safety of our products. As an industry leader, we continue to embrace our responsibility to do a better job communicating about the safety of our products by opening-up and giving interested citizens access to the safety studies we have submitted to regulatory authorities under the substance approval process. Improving access to the science behind our products is a key part of what we refer to as our Transparency Initiative. (cropscience-transparency.bayer.com.)

We are reaching out to you today because we are marking another development in our initiative: we are making the Bayer-owned glyphosate studies available on our website. This step follows last December's publication of more than 300 glyphosate safety study summaries. Access will now be enabled to all 107 Bayer-owned glyphosate safety study reports that were submitted to the European Food Safety Authority (EFSA) as part of the substance authorization process in the European Union (EU).

As with the other substances included within our Transparency Initiative so far, we are focusing on safety studies submitted under the substance authorization process for plant protection products in the EU to the EFSA. This includes studies on toxicology, residues, E-fate, and ecotoxicology on the active substance, as well as a representative formulation. We are only including studies that have been submitted for uses in the EU market, but not those that have been submitted in the U.S. and other countries for specific product formulations. The studies submitted to EFSA may also cover some studies that have been submitted to other regulatory authorities across the globe.

We can provide access only to those safety studies that are fully owned by Bayer. Bayer cannot offer access to studies that are owned by other companies. In the EU, glyphosate safety studies for the most recent active substance renewal were submitted with a joint submission under the so-called "Glyphosate Task Force" (GTF): a consortium of companies joining resources and efforts to renew the European glyphosate registration. Safety studies on glyphosate conducted by the GTF, and the data contained within these studies, are not wholly owned by Bayer. As a result, we are not automatically at liberty to disclose this information.

The full study reports are available on demand for non-commercial use upon request on our transparency website via an online order form. Recipients are granted a license to use one copy of the respective document. Any distribution, reproduction or publication requires the consent of Bayer AG (or its respective affiliate). Any use of the document or its content for regulatory or any other commercial purpose is prohibited and constitutes a violation of the underlying license agreement. For further details, please click here. If you have any questions or would like to learn more, please do not hesitate to reach out. Further information around the initiative can also be found in the FAQ section of our website.

Best regards,

Best regards,



Bayer – Crop Science Monsanto SAS Eden Park, Batiment B, 1, Rue Buster Keaton 69800, Saint-Priest France Tel: +32<sup>5.1.2.e Woo</sup> Fax: +32<sup>5.1.2.e Woo</sup> Mobile: +32<sup>5.1.2.e Woo</sup> E-mail: 5.1.2.e Woo Web: http://www.bayer.com

## /// Follow Bayer on:

/// Twitter /// Facebook /// Instagram /// LinkedIn /// YouTube

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.



**Objet :** AGG communication

Dear colleagues,

As we discussed during our meeting in Brussels, <sup>512e Woo</sup> and I investigated the possibility to hire an independent spokesperson from a communication agency as a 'voice and face' on behalf of the AGG. 5.2.1 Woo

Besides this we have a second question on the communication planning. During the meeting in Brussels someone briefly mentioned the idea to present the AGG-Member States 'live' during a kind of press meeting. We think it could be a valuable idea. The advantage is that we can

concentrate the questions and attention for the glyphosate admission, also in time. Being presented together at the same time prevents us from being played against each other. It also gives us the possibility to explain the assessment process once again (including the way an assessment report is written) and to stress the transparancy by mentioning on which moments the public will be informed about intermediate steps and results. The aim would be to have one clear start together and after that all doing our work in relative rest. We would like to hear your comments on this proposal.

Kind regards,

